Amiloride

ArtNr	HY-B0285-100mg
Hersteller	MedChem Express
CAS-Nr.	2609-46-3
Menge	100 mg
Quantity options	100 mg 10 mM/1 mL 1 ea
Kategorie	Oncology Cardiovascular Research Ischemia & Reperfusion Injury Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer
Typ	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]Ji, H.L., et al. delta ENaC: a novel divergent amiloride-inhibitable sodium channel. Am J Physiol Lung Cell Mol Physiol, 2012. 303(12): p. L1013-26.\|[2]Teiwes J, et al. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens. 2007 Jan;20(1):109-17.\|[3]Giamarchi A, et al. A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J. 2010 Apr 7;29(7):1176-91. ACS Nano. 2023 Apr 14.\|Adv Funct Mater. 2024 Oct 31.\|Adv Sci (Weinh). 2023 Dec 14:e2307880.\|Am J Transl Res. 2021 Jul 15;13(7):7538-7555.\|Cell Commun Signal. 2023 May 4;21(1):99.\|Cell Metab. 2022 Dec 6;34(12):2018-2035.e8.\|Cell Mol Biol Lett. 2024 Dec 3;29(1):149.\|Cell Physiol Biochem. 2018;51(6):2564-2574. \|Commun Biol. 2022 Nov 14;5(1):1248.\|Environ Sci Technol. 2021 Feb 11.\|FASEB J. 2025 Jan 15;39(1):e70298.\|Int J Biol Macromol. 2024 Aug 5;277(Pt 3):134517.\|J Am Chem Soc. 2018 Dec 12;140(49):17234-17240.\|J Control Release. 2024 Oct 26:S0168-3659(24)00725-9.\|J Leukoc Biol. 2024 Jul 16:qiae159.\|J Nanobiotechnology. 2020 Jan 31;18(1):26.\|J Pharm Anal. 2025 Jan 3.\|J Pharmaceut Biomed. 2020, 113870.\|Microb Pathog. 2019 Jul 18:103638. \|Mol Pharm. 2025 Mar 3.\|Nanotechnology. 2018 Feb 23;29(8):085101.\|Nat Biomed Eng. 2024 Sep 13.\|Nat Nanotechnol. 2024 Aug 26.\|Small Methods. 2020 Dec 18.\|Theranostics. 2019 May 31;9(13):3732-3753.\|Acta Pharm Sin B. 2024 Jul 27.\|Biomaterials. 2022 May;284:121529.\|Biosens Bioelectron. 2025 Jan 25:274:117184.\|Br J Pharmacol. 2020 Aug;177(15):3473-3488. \|Cell Mol Immunol. 2024 Jun 13.\|Cell Rep. 2022 May 31;39(9):110880.\|Food Chem. 2024 Sep 8;463(Pt 1):141196.\|Int J Biol Macromol. 14 March 2022.\|iScience. 19 October 2022, 105403.\|J Ethnopharmacol. 2022 Mar 5;115171.\|J Neuroinflammation. 2022 Feb 22;19(1):53.\|mBio. 2025 Feb 18:e0378724.\|Sci Total Environ. 2021, 146523.\|Theranostics. 2020 May 17;10(15):6581-6598. \|Transl Res. 2023 Sep 5;S1931-5244(23)00143-3.
Smiles	O=C(C1=NC(Cl)=C(N)N=C1N)NC(N)=N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MK-870
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	Apoptosis; Sodium Channel; TRP Channel
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	229.631
Product Description	Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC[1]) and urokinase-type plasminogen activator receptor (uTPA[2]). Amiloride is a blocker of polycystin-2 (PC2; TRPP2[3]) channel.
Manufacturer - Research Area	Metabolic Disease; Cardiovascular Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Membrane Transporter/Ion Channel; Neuronal Signaling
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-B0285-100mg-safety-datasheet.pdf